Using real-world data to evaluate biosimilar switching

被引：0

作者：

Dutcher, Sarah K. ^{[1
]}

Eworuke, Efe ^{[1
]}

Blum, Michael D. ^{[1
]}

Ball, Robert ^{[1
]}

机构：

[1] US FDA, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷 / 07期

关键词：

INFLIXIMAB;

D O I：

10.1002/pds.4899

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：814 / 816

页数：3

共 19 条

[1] Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System [J].

Agboola, Foluso ;

Reddy, Prabashni .

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (12) :1214-1218

[2]

[Anonymous], 2015, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

[3]

[Anonymous], GUID IND FDA STAFF B

[4] Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review [J].

Bakalos, Georgios ;

Zintzaras, Elias .

CLINICAL THERAPEUTICS, 2019, 41 (01) :155-173

[5] Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study [J].

Benucci, Maurizio ;

Li Gobbi, Francesca ;

Bandinelli, Francesca ;

Damiani, Arianna ;

Infantino, Maria ;

Grossi, Valentina ;

Manfredi, Mariangela ;

Parisi, Simone ;

Fusaro, Enrico ;

Batticciotto, Alberto ;

Sarzi-Puttini, Piercarlo ;

Atzeni, Fabiola ;

Meacci, Francesca .

IMMUNOLOGIC RESEARCH, 2017, 65 (01) :419-422

[6] Counterpoint: The Treatment Decision Design [J].

Brookhart, M. Alan .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2015, 182 (10) :840-845

[7] Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy [J].

Chen, Chao ;

Hartzema, Abraham G. ;

Xiao, Hong ;

Wei, Yu-Jung ;

Chaudhry, Naueen ;

Ewelukwa, Ofor ;

Glover, Sarah C. ;

Zimmermann, Ellen M. .

INFLAMMATORY BOWEL DISEASES, 2019, 25 (08) :1417-1427

[8] Biosimilars: The US Regulatory Framework [J].

Christl, Leah A. ;

Woodcock, Janet ;

Kozlowski, Steven .

ANNUAL REVIEW OF MEDICINE, VOL 68, 2017, 68 :243-254

[9] Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars [J].

Desai, Rishi J. ;

Kim, Seoyoung C. ;

Curtis, Jeffrey R. ;

Bosco, Jaclyn L. F. ;

Eichelberger, Bernadette ;

Barr, Charles E. ;

Lockhart, Catherine M. ;

Bradbury, Brian D. ;

Clewell, Jerry ;

Cohen, Hillel P. ;

Gagne, Joshua J. .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (07) :757-769

[10] Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population [J].

Doshi, Jalpa A. ;

Takeshita, Junko ;

Pinto, Lionel ;

Li, Penxiang ;

Yu, Xinyan ;

Rao, Preethi ;

Viswanathan, Hema N. ;

Gelfand, Joel M. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (06) :1057-U409

← 1 2 →